In accordance with the requirements under Colorado Statute § 12-42.5-308, LEO Pharma Inc. is providing the following information to Colorado Prescribers:

Product	Package Size	WAC Per Package Size*
Adbry® (tralokinumab-ldrm), 150 mg/mL solution in a	One carton containing 2	
single-dose prefilled syringe with needle guard	prefilled syringes	\$1,919.52
Adbry® (tralokinumab-ldrm), 150 mg/mL solution in a	Two cartons (multipack)	
single-dose prefilled syringe with needle guard	containing 4 prefilled syringes	\$3,839.03

There are no FDA approved biologic products from the same therapeutic class.\*\*

<sup>\*</sup>The wholesale acquisition cost (WAC) price set forth herein reflects the undiscounted list price to wholesalers without regard to prompt pay or other discounts, rebates, or other price reductions. The WAC may not represent actual costs to patients, payers and health systems and should not be considered a reflection of the actual transaction prices. The price paid by patients is often different than the WAC price, and most patients will not pay the WAC price. How much a patient will pay will depend on several factors, including the patient's insurance coverage, and any discount or other programs that the patient may be eligible to participate in.

<sup>\*\*</sup>This list does not imply that the products are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.

In accordance with the requirements under Colorado Statute § 12-42.5-308, LEO Pharma Inc. is providing the following information to Colorado Prescribers:

Product	Package Size	WAC Per Package Size*
Enstilar® (calcipotriene and betamethasone dipropionate)		
Foam, 0.005%/0.064%	60 g	\$1,327.31
Enstilar® (calcipotriene; betamethasone dipropionate)		
Foam, 0.005%/0.064%		
	120 g	\$2,654.60

There is one FDA approved generic therapeutic equivalent generic\*\*: calcipotriene and betamethasone dipropionate

<sup>\*</sup>The wholesale acquisition cost (WAC) price set forth herein reflects the undiscounted list price to wholesalers without regard to prompt pay or other discounts, rebates, or other price reductions. The WAC may not represent actual costs to patients, payers and health systems and should not be considered a reflection of the actual transaction prices. The price paid by patients is often different than the WAC price, and most patients will not pay the WAC price. How much a patient will pay will depend on several factors, including the patient's insurance coverage, and any discount or other programs that the patient may be eligible to participate in.

<sup>\*\*</sup>This list does not imply that the products are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.

# In accordance with the requirements under Colorado Statute § 12-42.5-308, LEO Pharma Inc. is providing the following information to Colorado Prescribers:

Product	Package Size	WAC Per Package Size*
Finacea® (azelaic acid) Foam, 15%	50 g	\$435.84

#### There are no FDA approved generic therapeutic equivalents.\*\*

Product	Package Size	WAC Per Package Size*
Finacea® (azelaic acid) Gel, 15%	50 g	\$395.36

There are four FDA approved generic therapeutic equivalents and one authorized generic\*\*:

• azelaic acid gel

<sup>\*</sup>The wholesale acquisition cost (WAC) price set forth herein reflects the undiscounted list price to wholesalers without regard to prompt pay or other discounts, rebates, or other price reductions. The WAC may not represent actual costs to patients, payers and health systems and should not be considered a reflection of the actual transaction prices. The price paid by patients is often different than the WAC price, and most patients will not pay the WAC price. How much a patient will pay will depend on several factors, including the patient's insurance coverage, and any discount or other programs that the patient may be eligible to participate in.

<sup>\*\*</sup>This list does not imply that the products are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.

In accordance with the requirements under Colorado Statute § 12-42.5-308, LEO Pharma Inc. is providing the following information to Colorado Prescribers:

Product	Package Size	WAC Per Package Size*
Taclonex <sup>®</sup> (calcipotriene and betamethasone dipropionate)		
Topical Suspension 0.005%/0.064%	60 g	\$1,302.02
Taclonex <sup>®</sup> (calcipotriene and betamethasone dipropionate)		
Topical Suspension 0.005%/0.064%	120 g	\$2,604.04

There are three FDA approved generic therapeutic equivalent and one authorized generic\*\*:

• Calcipotriene 0.005% and betamethasone dipropionate 0.064% topical suspension

Product	Package Size	WAC Per Package Size*
Taclonex® (calcipotriene 0.005% and betamethasone		
dipropionate 0.064%) Ointment	60 g	\$1,188.82

There is one FDA authorized generic therapeutic equivalent\*\*:

• Calcipotriene 0.005% and betamethasone dipropionate 0.064% ointment

There are two FDA approved generic therapeutic equivalents\*\*:

• Calcipotriene 0.005% and betamethasone dipropionate 0.064% ointment

<sup>\*</sup>The wholesale acquisition cost (WAC) price set forth herein reflects the undiscounted list price to wholesalers without regard to prompt pay or other discounts, rebates, or other price reductions. The WAC may not represent actual costs to patients, payers and health systems and should not be considered a reflection of the actual transaction prices. The price paid by patients is often different than the WAC price, and most patients will not pay the WAC price. How much a patient will pay will depend on several factors, including the patient's insurance coverage, and any discount or other programs that the patient may be eligible to participate in.

<sup>\*\*</sup>This list does not imply that the products are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.

In accordance with the requirements under Colorado Statute § 12-42.5-308, LEO Pharma Inc. is providing the following information to Colorado Prescribers:

Product	Package Size	WAC Per Package Size*
Protopic® (tacrolimus) Ointment, 0.03%	30 g	\$289.84
Protopic® (tacrolimus) Ointment, 0.03%	60 g	\$579.69
Protopic® (tacrolimus) Ointment, 0.1%	30 g	\$289.84
Protopic® (tacrolimus) Ointment, 0.1%	60 g	\$579.69
Protopic® (tacrolimus) Ointment, 0.1%	100 g	\$966.15

There is one FDA authorized generic therapeutic equivalent\*\*:

• Tacrolimus ointment 0.03% and 0.1%

There are three FDA approved generic therapeutic equivalents\*\*:

• Tacrolimus ointment 0.1%

There are two FDA approved generic therapeutic equivalents\*\*:

• Tacrolimus ointment 0.03%

\*The wholesale acquisition cost (WAC) price set forth herein reflects the undiscounted list price to wholesalers without regard to prompt pay or other discounts, rebates, or other price reductions. The WAC may not represent actual costs to patients, payers and health systems and should not be considered a reflection of the actual transaction prices. The price paid by patients is often different than the WAC price, and most patients will not pay the WAC price. How much a patient will pay will depend on several factors, including the patient's insurance coverage, and any discount or other programs that the patient may be eligible to participate in.

\*\*This list does not imply that the products are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.